<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684342</url>
  </required_header>
  <id_info>
    <org_study_id>Fungal infection in ICU</org_study_id>
    <nct_id>NCT04684342</nct_id>
  </id_info>
  <brief_title>Fungal Infection in Patients in Intensive Care Units</brief_title>
  <official_title>Predictors of Fungal Infection in Non-neutropenic Patients in Intensive Care Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Predictors of fungal infection in non-neutropenic patients in intensive care units and the&#xD;
      aim of the study is To evaluate the frequency of fungal infection in non-neutropenic patients&#xD;
      in Intensive Care Units.&#xD;
&#xD;
      To evaluate the risk factors of fungal infection in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of candidemia in the overall population ranges from 1.7 to 10 episodes per&#xD;
      100,000 inhabitants and Candida is one of the ten leading causes of bloodstream infections in&#xD;
      developed countries. An estimated 33-55% of all episodes of candidemia occur in intensive&#xD;
      care units (ICU) and are associated with mortality rates ranging from 5% to 71%. Candida&#xD;
      fungemia may have an endogenous or an exogenous origin, and in recent years a growing&#xD;
      proportion of episodes of candidemia have been caused by Candida species other than albicans.&#xD;
      The most important independent conditions predisposing to candidemia in ICU patients include&#xD;
      prior abdominal surgery, intravascular catheters, acute renal failure, parenteral nutrition,&#xD;
      broad-spectrum antibiotics, a prolonged ICU stay, the use of corticosteroids and mucosal&#xD;
      colonization with Candida. In recent years, several studies have shown that ICU patients with&#xD;
      mucosal Candida colonization, particularly if multifocal, are at a higher risk for invasive&#xD;
      candidiasis, and that colonization selects a population amenable to antifungal prophylaxis or&#xD;
      empirical therapy. Candidemia in ICUs is associated with a con- siderable increase in&#xD;
      hospital costs and length of hospital stay.&#xD;
&#xD;
      Invasive fungal infection (IFI) is a grave infection associated with serious effects in&#xD;
      patients with chronic diseases including liver cirrhosis. The diagnosis of IFI re- quires&#xD;
      histopathological evidence of tissue invasion, or isolation in blood cultures, or isolation&#xD;
      from a normally sterile body fluid or site, with samples collected intra-op- eratively or by&#xD;
      percutaneous needle aspiration. Awareness of IFI has been increased in clinical practice with&#xD;
      the increased survival of patients in immunocompromised states. Such infections are&#xD;
      associated with a high morbidity and significant mortality, requiring early diagnosis and&#xD;
      appropriate treatment, but also optimal prophylaxis in patients at high risk.&#xD;
&#xD;
      Globally, several studies had assessed fungal infections in non-neutropenic patients,&#xD;
      however, to our knowledge, searching for fungal infections in these patients are un-&#xD;
      derestimated in our locality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of fungal infection in cirrhotic patients</measure>
    <time_frame>4 months</time_frame>
    <description>frequency of fungal infection in cirrhotic patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>cirrhotic ICU Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>about 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Routine Laboratory investigations</intervention_name>
    <description>Complete blood picture&#xD;
Liver function test and prothrombine time &amp; concentration.&#xD;
Blood urea and creatinine&#xD;
Blood glucose, serum Na and K&#xD;
CRP and ESR&#xD;
Clinical specimens will be collected from patients according to the suspected site of infection (e.g. blood, urine, ascitic fluid, sputum or endo- tracheal aspirates) VITEK 2Compact inflammatory markers</description>
    <arm_group_label>cirrhotic ICU Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult Patients with liver cirrhosis that will be clinically suspected to have in-&#xD;
             fection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Zakaria, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud A. Abdelmoula</last_name>
    <phone>01113983636</phone>
    <phone_ext>+2</phone_ext>
    <email>abdou.mahmoud93@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet. 2006 Jan 7;367(9504):52-6. Erratum in: Lancet. 2006 Feb 25;367(9511):650.</citation>
    <PMID>16399153</PMID>
  </reference>
  <reference>
    <citation>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 Apr;57(4):1651-3. doi: 10.1002/hep.26359.</citation>
    <PMID>23463403</PMID>
  </reference>
  <reference>
    <citation>Bucsics T, Schwabl P, Mandorfer M, Peck-Radosavljevic M. Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). J Hepatol. 2016 Jun;64(6):1452-4. doi: 10.1016/j.jhep.2016.01.039. Epub 2016 Feb 23.</citation>
    <PMID>26916528</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mahmoud Abdou Mahmoud</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

